ARTL
Artelo Biosciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 2
Stock Price Surged Significantly
Significant Net Income Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ARTL
Artelo Biosciences, Inc.
A clinical-stage biopharmaceutical company developing cannabinoid-based therapies for cancer, pain, and inflammatory diseases
505 Lomas Santa Fe
, Suite 160
, Solana Beach
, CA USA 92075
--
Artelo Biosciences, Inc., was incorporated in Nevada on May 2, 2011. The Company is a clinical biopharmaceutical company dedicated to the development and commercialization of therapies designed to modulate endogenous signaling pathways, including the endocannabinoid system (" ECS "), an array of receptors and neurotransmitters that form a biochemical communication network throughout the body.
Company Financials
EPS
ARTL has released its 2025 Q3 earnings. EPS was reported at -3.97, versus the expected -0.82, missing expectations. The chart below visualizes how ARTL has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
